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2013, accepted Fearavalvular aortic regurgitation (PAR) negatively affects the prognosis after transcatheter aortic valve replacement
(TAVR) with dramatically increased morbidity and mortality in patients with more than mild PAR. Because
transcatheter heart valves are implanted in a sutureless fashion using oversizing to anchor the prosthesis stent frame
at the level of the virtual aortic annulus, stent frame underexpansion due to heavily calciﬁed cusps, suboptimal
placement of the prosthesis, and/or annulus-prosthesis-sizemismatch due tomalsizing can contribute to paravalvular
leakage. In contrast to open heart surgery, TAVR does not offer the opportunity to measure the aortic annulus under
direct vision during the procedure. Therefore, the dilemma before each TAVR procedure is the appropriate sizing of the
dimensions of the aortic annulus and to choose not only the size but also the transcatheter heart valve type
(self-expanding vs. balloon-expandable) that ﬁts the given anatomy best. Because precise echocardiographic
quantiﬁcation of PAR in patients with TAVR remains challenging especially in the acute implantation situation,
a multimodal approach for the evaluation of PAR with the use of hemodynamic measurements and imaging
modalities is imperative to precisely quantify the severity of aortic regurgitation immediately after valve implantation
and to identify patients who will beneﬁt from corrective measures such as post-dilation or valve-in-valve implantation.
Every measure has to be taken to prevent or reduce PAR to provide a satisfying long-term clinical outcome.
(J Am Coll Cardiol 2013;62:11–20) ª 2013 by the American College of Cardiology FoundationTranscatheter aortic valve replacement (TAVR) has become
an alternative to surgical aortic valve replacement for inop-
erable or surgical high-risk patients with severe aortic
stenosis and prohibitive surgical risk (1,2). Transcatheter
heart valves (THVs) are implanted in a sutureless fashion
using oversizing to anchor the prosthesis stent frame at the
level of the aortic annulus. Therefore, incomplete circum-
ferential apposition of the prosthesis with the annulus might
lead to paravalvular aortic regurgitation (PAR). Because
PAR negatively affects the prognosis after TAVR with
dramatically increased morbidity and mortality in patients
with more than mild PAR (3–16), this procedure-related
issue has to be addressed to further improve the outcome
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bruary 5, 2013.This paper reviews the evaluation of signiﬁcant PAR in
patients with TAVR with a focus on precise quantiﬁcation
and therapeutic options to manage PAR after TAVR.Background
Anatomy of the aortic valve. Precise assessment of the
dimensions of the aortic valvular complex is fundamental
before each TAVR procedure. Although the concept of an
annulus is ingrained in the surgical vocabulary, the aortic
root is not constructed on the basis of a ring-like structure
supporting the leaﬂets of the aortic valve. The true histo-
logical ventricular–aortic junction, which is circular but
crossed by the semilunar attachments of the leaﬂets of the
aortic valve in a crown-like fashion (the “surgical” annulus)
within the cylindrical aortic root, cannot be seen on multi-
slice computed tomography or other noninvasive imaging
modalities (17,18). Therefore, the so-called aortic annulus is
deﬁned as a virtual ring that has three anchor points at the
nadir of each of the attachments of the aortic cusps (Fig. 1).
This virtual aortic annulus is mostly noncircular and often
may have an oval or elliptical shape (17–22).
Abbreviations
and Acronyms
AR = aortic regurgitation
ARI = aortic regurgitation
index
LV = left ventricle
LVEDP = left ventricular
end-diastolic pressure
LVOT = left ventricular
outﬂow tract
PAR = paravalvular aortic
regurgitation
TAVR = transcatheter aortic
valve replacement
TEE = transesophageal
echocardiography
THV = transcatheter heart
valve
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PAR results from incomplete
circumferential apposition of the
prosthesis with the annulus. Dis-
cordance in the orthogonal dia-
meters of oval-shaped annuli with
the circular prosthesis leads to
prosthetic undersizing or over-
sizing, a cause of signiﬁcant PAR
or annular rupture (21). Degen-
erative calciﬁcation of the native
aortic valve (e.g., severely calciﬁed
cusp) causes PAR through mal-
apposition of the skirt with the
annulus or displacement of the
prosthesis into a high or low po-
sition within the aortic rootFigure 1 Anatomy of the Aortic Root
The aortic root with the aortic valve, which is suspended in a crown-like fashion
within the root, contains 3 circular rings (A): the sinotubular junction, the
“surgical” annulus (anatomic ventriculo-arterial junction), and the virtual aortic
annulus, which is formed by joining the nadir of each aortic valvular cusp (B).
VA ¼ virtual aortic.(6,22). It may hamper proper positioning of the THV
and contribute to the occurrence of signiﬁcant PAR after
TAVR (23).
Another risk factor for PAR is a functional bicuspid aortic
valve, which is predominantly caused by fusion of the
commissures as a consequence of heavy calciﬁcation that may
preclude the expansion of the prosthesis and full apposition of
the THV with the annulus. On a compassionate off-label
basis, early results of TAVR for bicuspid aortic valve
stenosis seem promising, and most cases of PAR are mild
(24–26). However, the long-term impact of noncircular
prosthesis expansion on hemodynamics and durability of the
THVhas to be elucidated before TAVR can be recommended
in patients with bicuspid aortic stenosis.
Clinically signiﬁcant acute AR is characterized by
a considerable diastolic runoff into the left ventricle (LV)
leading to acute volume overload, which has a disastrous
effect, especially in patients with severely impaired left
ventricular function: The noncompliant, hypertrophic LV,
which has been adapted to chronic pressure overload, is
unable to increase the end-diastolic volume, so that the left
ventricular end-diastolic pressure (LVEDP) increases
rapidly with consecutive decrease of cardiac output leading
to hemodynamic deterioration (27,28).
Several studies have shown that up to 70% of all patients
with TAVR have PAR after the procedure, graded as
moderate or severe in approximately 15% of the patients
(Table 1). Meanwhile, it is well recognized that the occur-
rence of more than mild PAR has a signiﬁcant impact on
prognosis after TAVR with a two- to four-fold increased
1-year mortality risk compared with patients without clini-
cally signiﬁcant PAR (6–16). In 3,195 patients of the
prospective FRANCE-2 (French Aortic National Core-
Valve and Edwards Registry 2) TAVR registry, the inves-
tigators observed that patients with a more than mild PAR
had a 2.5-fold increased mortality risk compared with
patients without PAR or with only mild PAR (11). The 2-year results of the PARTNER (Placement of Aortic
Transcatheter Valves) Trial cohort A (10) even suggested
that a lesser extent of PAR may be harmful for patients with
TAVR. Therefore, the precise quantiﬁcation of the severity
of AR immediately after valve implantation (within the
catheterization laboratory) is paramount to identify patients
with clinically signiﬁcant PAR.
Imaging Before and After TAVR
In contrast to open heart surgery, TAVR does not offer the
opportunity to measure the aortic annulus under direct
vision during the procedure. Therefore, the dilemma before
each TAVR procedure is the appropriate sizing of the
dimensions of the aortic annulus and to choose not only the
size but also the THV type (self-expanding vs. balloon-
expandable) that ﬁts the given anatomy best.
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13Two-dimensional transesophageal echocardiography
(TEE) is not sufﬁcient for accurate THV sizing and tends to
underestimate the real dimension of the aortic annulus,
because the basal attachments of the aortic leaﬂets are cut
but the maximum diameter of the aortic annulus is not
transected (18,21). Therefore, pre-procedural 3-dimensional
imaging techniques for detailed and accurate assessment of
the annulus are essential to reduce the incidence of para-
valvular leakage after TAVR (21,29–33). For TAVR
planning, multislice computed tomography is the gold
standard because it permits precise measurement of the aortic
root at any desired level or plane, and thus may provide more
accurate measurement. Because the aortic annulus is often
oval shaped, it is recommended to measure both the
maximum and the minimum diametersdor even more
pragmatic, the perimeter or area of the annulusdfor precise
sizing of the THV. With respect to annulus area or perim-
eter, an oversizing by more than 10% seems to be associated
with a lesser extent of PAR (6,16,21,32,34).
Angiographic Assessment of PAR
The qualitative angiographic grading of PAR is an easy-
to-use method, but regurgitant ﬂow within each angio-
graphic grade varies widely, and a considerable overlap from
one grade to another has been reported (35,36). However, in
recent TAVR studies, the angiographically assessed (quali-
tative) degree of PAR correlated well with echocardiography
in patients with TAVR (6,34). PAR can be classiﬁed
according to the visually estimated density of opaciﬁcation of
the LV into three degrees adapted to the Valve Academic
Research Consortium 2 criteria: mild (reﬂow of contrast in
the outﬂow tract and middle portion of the LV but clearing
with each beat), moderate (reﬂow of contrast in the whole
left ventricular cavity with incomplete washout in a single
beat and faint opaciﬁcation of the entire LV over several
cardiac cycles), and severe (opaciﬁcation of the entire LV
with the same intensity as in the aorta and persistence of the
contrast after a single beat). Because many patients with
TAVR undergo the procedure in conscious sedation and
therefore the implantation of the valve prosthesis is
predominantly angiographically guided, the amount of
contrast dye should be kept as low as possible, especially in
patients with chronic renal failure and/or at high risk for the
occurrence of acute kidney injury (3,7).
Echocardiographic Assessment
Despite the recently updated Valve Academic Research
Consortium 2 criteria, which refer to parameters recom-
mended for surgical prosthetic heart valves that have yet to
be validated in THVs, the echocardiographic quantiﬁcation
of PAR after TAVR remains challenging (37,38). Even the
use of an integrative echocardiographic approach for grading
aortic regurgitation (AR) remains imprecise in practice,
especially in the implantation situation, for the following
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14reasons: 1) the acute hemodynamic changes that occur
during TAVR affect Doppler and color ﬂow assessment;
2) semiquantitative parameters of AR severity, such as jet
width, vena contracta, or pressure half-time, are best applied
in central jets and thus are not ideal for quantiﬁcation of the
eccentric, circumferential PAR jets seen in patients with
TAVR; and 3) acoustic shadowing by the prosthesis and
native calciﬁcation also may obscure PAR jets. Given these
quantitative limitations, TEE screening criteria include a jet
depth extending beyond the left ventricular outﬂow tract
(LVOT), multiple PAR jets, and holodiastolic ﬂow reversal
in the descending aorta (37). Prominent holodiastolic ﬂow
reversal in the descending aorta identiﬁes patients with more
than mild PAR with a sensitivity of up to 86% and rules out
signiﬁcant PAR with a speciﬁcity of up to 92% (p < 0.001)
(6,13). In addition, it is desirable to measure the circum-
ferential extent of the jet in the short-axis view in patients
with clinically signiﬁcant PAR (<10%: mild, 10% to 29%:
moderate, and 30%: severe PAR) (37). However, it is
important to realize that at this time, the body of evidence
supporting these criteria for the assessment of paravalvular
AR may be limited and requires further validation in
patients with THV as our experience continues to expand.
Nonetheless, TEE has an essential role in deﬁning the
origin and mechanism of PAR. The jets of transvalvular ARFigure 2 Origin and Mechanism of Paravalvular Aortic Regurgitation
Transesophageal echocardiography (TEE) long-axis view of Edwards SAPIEN (Edwards Life
and PAR (A, Online Video 1). PAR after deployment of an Edwards SAPIEN XT 26-mm pros
the root (B, Online Video 2). TEE short-axis view of underexpanded oval-shaped waist of a M
TEE long-axis view of an Edwards SAPIEN XT 26-mm prosthesis with diameters of 24 to 26
TEE of malposition PAR after low implantation of a Medtronic CoreValve prosthesis. The P
(“supra-skirt” PAR) into the paravalvular space and LVOT (E, Online Video 3). TEE of malpos
posterior PAR jet passes from the aortic sinus below the tissue skirt (“infra-skirt” PAR) int
Video 4). AR ¼ aortic regurgitation.are easy to differentiate from PAR, lying within the
circumference of the prosthetic stent frame (Fig. 2A,
Online Video 1). The valve leaﬂets should be assessed to
determine whether there is structural damage causing
transleaﬂet AR, intact leaﬂets with insufﬁcient diastolic
pressure to close them, or central leaﬂet malapposition
related to the prosthetic design or tissue. Malapposition
paravalvular AR jets occur outside the circumference of the
prosthetic stent frame. These jets are caused by incomplete
apposition between the prosthesis and the annulus because of
heavy calciﬁcation or underexpansion of the prosthesis
(Fig. 2B, Online Video 2). TEE assessment of prosthetic
geometry (circular or noncircular) (Fig. 2C) and in vivo
diameter may be required to guide treatment (Fig. 2D).
Furthermore, malposition PAR jets may occur across the
stent frame, when the prosthesis is implanted in too low or
too high a position relative to the native annulus. In the low
implant (“too ventricular”), the prosthesis is deployed at
a depth that exceeds the height of its tissue skirt; the PAR
jet passes above the skirt (“supra-skirt” PAR), from within
the aortic portion of the stent frame into the paravalvular
space and the LVOT (Fig. 2E, Online Video 3). In the high
implant (“too aortic”), the prosthesis is deployed partially
above the native annulus; the PAR jet passes from the
paravalvular space across the irregular inﬂow edge of the(PAR)
sciences Corporation, Irvine, California) 23-mm prosthesis with both transvalvular AR
thesis because of malapposition with the left annulus. The device was not co-axial to
edtronic CoreValve 29-mm prosthesis (Medtronic Inc., Minneapolis, Minnesota) (C).
mm indicating reasonable expansion in the presence of PAR (D). Color 3-dimensional
AR jet passes from within the aortic portion of the stent frame above the tissue skirt
ition PAR after the high implantation of a Medtronic CoreValve 29-mm prosthesis. The
o the LVOT where the irregular inﬂow edge rises above the native annulus (F, Online
JACC Vol. 62, No. 1, 2013 Sinning et al.
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15prosthesis into the LVOT (“infra-skirt” PAR) (Fig. 2F,
Online Video 4).
Hemodynamic Assessment During TAVR
Because an objective and quantitative parameter for the
direct assessment of the severity of PAR during the proce-
dure would be invaluable in patients with TAVR to apply
effective measures to reduce the severity of PAR, the use of
hemodynamic parameters for a quantitative evaluation of
PAR seems to be useful. The so-called aortic regurgitation
index (ARI) is the ratio of the transvalvular gradient between
diastolic blood pressure (RRdia) in the aorta and LVEDP
to systolic blood pressure (RRsys) in the aorta: [(RRdia –
LVEDP)/RRsys]  100 (Figs. 3A and 3B) (6). The ARI
was developed in a cohort of TAVR patients from Bonn,
Germany, and was validated in an independent TAVR
cohort from Leicester, United Kingdom (6,13). The ARI
shows an inverse correlation to the severity of PAR; differ-
entiates between patients with mild, moderate, or severe
PAR; and independently predicts the associated 1-year
mortality risk. In both cohorts, an ARI cutoff value of 25
was calculated by receiver operating curve analysis as the
optimal predictor of the 1-year mortality risk after TAVR.Figure 3 ARI in Patients With Moderate and Trivial PAR
After adjustment for the systolic blood pressure level, the transvalvular gradient
results in an ARI of 16.7 in a patient with moderate PAR (A) and an ARI of 30.8 in
a patient with trivial PAR (B). LVEDP ¼ left-ventricular end-diastolic blood pressure;
RRdia ¼ end-diastolic blood pressure in the aorta; RRsys ¼ systolic blood pressure
in the aorta.In addition, this ARI cutoff value had a negative predictive
value of 95% to 100% for the occurrence of more than mild
PAR, when used complementary to the angiographically
or echocardiographically assessed PAR severity (6,13).
Although the ARI does not consider the severity of pre-
procedural AR and concomitant mitral regurgitation, it is
a helpful tool to identify patients after TAVR with the need
to take effective corrective measures to decrease the severity
of PAR. Another study on the impact of PAR on long-term
outcome recently conﬁrmed that the ARI signiﬁcantly
differed between patients with moderate/severe PAR com-
pared to patients with no or mild PAR (16). However,
the ARI still has to be validated in a larger and controlled
study population.
When evaluating hemodynamics after TAVR with the
dimensionless ARI, it is recommended to perform the
measurements approximately 10 min after valve deployment
to prevent confounding by an increased LVEDP due to
myocardial ischemia and/or diastolic dysfunction after rapid
pacing and balloon valvuloplasty. The determination of the
ARI should be performed as mean value over several cardiac
cycles (especially in patients with atrial ﬁbrillation) with
a heart rate of 60 to 80 beats/min and without extrasystolic
beats, because with increasing heart rate and shortened
duration of the diastole, the diastolic pressure in the aorta also
increases and therebymight lead to a false-negativeARI above
the cutoff of 25.
Treatment Options to Reduce PAR
Several corrective measures have been proposed to overcome
signiﬁcant residual PAR after TAVR. However, data on
these measures predominantly originate from small series or
case reports, and the impact of corrective measures for the
reduction of PAR on long-term outcome and especially
valve durability still has to be clariﬁed in future studies
(39–45).
A standardized algorithm with a multimodal approach
might be helpful for the evaluation of PAR after TAVR to:
1) quantify the severity of AR immediately after valve
implantation (within the catheterization laboratory); 2)
evaluate the hemodynamic tolerability of PAR with regard
to the prognosis after TAVR; and 3) identify patients who
will beneﬁt from corrective measures, such as post-dilation
or valve-in-valve implantation to reduce PAR and improve
outcome (Fig. 4). After valve deployment, the degree of
PAR can be assessed by aortic root angiography or echo-
cardiography. If no PAR is present, no measures have to be
taken. In all other cases with mild to severe PAR, the
determination of the ARI is helpful to more precisely
quantify the extent of PAR and to have a point of reference
before corrective measures are taken. In patients with more-
than-mild PAR and/or an ARI <25, the evaluation of PAR
by echocardiography, preferably TEE, is recommended to
elucidate the cause of PAR and its mechanism. When
corrective measures have been taken in patients with
Figure 4 Treatment Algorithm for PAR After TAVR
Treatment algorithm using a multimodal approach with the use of hemodynamic measurements and imaging modalities to quantify the severity of PAR during the TAVR procedure
and to identify patients who will beneﬁt from corrective measures. AR ¼ aortic regurgitation; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography.
Figure 5 Balloon Post-Dilation
Underexpansion of a CoreValve 29-mm prosthesis frame caused by a severely calciﬁed cusp (A) resulted in moderate PAR with an eccentric jet near the left coronary cusp in
aortic root angiography (B, arrows show eccentric AR jet) and an ARI of 20.8 (C). Post-dilation with a straight 28-mm valvuloplasty balloon (D) led to a satisfying procedural result
with only mild PAR (E) and increased the ARI to 31.8 (F). AR ¼ aortic regurgitation.
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Figure 6 Valve-in-Valve Implantation
Deep (“too ventricular”) implantation of a CoreValve 31-mm prosthesis (A) led to severe PAR in aortic root angiography (B, arrows show supra-skirt PAR) and an ARI of 14.3,
reﬂecting unfavorable hemodynamics (C). After implantation of a second CoreValve 31-mm prosthesis in valve-in-valve-technique, which was delivered 5 mm higher than the ﬁrst
CoreValve under TEE control (D), only trivial PAR was left in angiography (E), and the ARI increased from 14.3 to 45.8, indicating a good procedural result (F). Abbreviation as in
Figure 5.
Figure 7 Snare Technique
Deep implantation of a CoreValve prosthesis (left coronary cusp: 13.2 mm; noncoronary cusp: 12.3 mm) resulted in severe “supra-skirt” PAR (A, B) with beginning equalization
between the diastolic blood pressure in the aorta and the left ventricular end-diastolic pressure (LVEDP), resulting in an ARI of 16.0 (C). TEE showed the circumferential extent of
massive paravalvular leakage (D). Via left-sided transbrachial access, the CoreValve prosthesis was pulled into a more favorable position (left coronary cusp: 4.2 mm; non-
coronary cusp: 2.6 mm) with use of an Amplatz (AGA Medical Corp., Plymouth, Minnesota) gooseneck snare catheter (E), resulting in an ARI of 32.1 (F) without evidence of
residual PAR (E). Abbreviation as in Figure 5.
JACC Vol. 62, No. 1, 2013 Sinning et al.
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18clinically signiﬁcant PAR, the severity of PAR can be re-
evaluated by imaging modalities and the AR index.
Balloon Post-Dilation
The presence of severely calciﬁed cusps of the native aortic
valve might prevent complete apposition of the prosthesis
with the annulus leading to a typical eccentric AR jet
(Fig. 5). Several studies identiﬁed a higher degree of native
aortic valve calciﬁcation as a predictor of more than mild
PAR (22,46). Balloon post-dilation is an option to reduce
the degree of PAR by obtaining a better expansion of the
prosthesis stent frame and a better sealing of the paravalvular
space if the THV has been deployed at the correct
implantation depth (6,26,40–43,45,47). Post-dilation is also
the treatment option of choice for patients with frame
underexpansion as the reason for severe PAR that can occur
in rare casesddespite predilation of the native aortic
valvedwith the use of self-expanding THVs (48).
The size of the balloon for post-dilation should conform to
the aortic annulus dimension and not exceed the maximum
diameter of the native aortic valve. For the Medtronic Cor-
eValve prosthesis (Medtronic Inc.,Minneapolis,Minnesota),
a straight valvuloplasty balloon with a maximum diameter of
22, 25, 28, and 29 mm is recommended for the 23-, 26-, 29-,
and 31-mm CoreValve, respectively (6). For the EdwardsFigure 8 Interventional Closure of Paravalvular Leakage
Despite balloon post-dilation and oversizing with a straight 22-mm valvuloplasty balloon,
23-mm prosthesis with the annulus caused by a severely calciﬁed cusp (A, B) remained 2
depth and showed an unfavorable ARI of 21.7 (C). TEE was used to identify the PAR pat
paravalvular defect was obtained with use of a straight hydrophilic wire over a diagnostic
Edwards SAPIEN prosthesis. Before insertion of the 9F delivery sheath, the THV was secu
placed in the LV to control the Edwards SAPIEN prosthesis in case of dislodgement or em
real-time 3-dimensional TEE and successful leak closure with only trace PAR left in angioSAPIEN prosthesis (Edwards Lifesciences Corporation,
Irvine, California), balloon post-dilation should be performed
with the same balloon as used for delivery of the valve pros-
thesis stepwise adding 1 ml saline to the total volume to
increase its diameter (43). In a recent study, THV oversizing
after deployment by post-dilation did not lead to leaﬂet
malapposition with consecutive central AR (15,43).
Valve-in-Valve Implantation
Accurate positioning of the THV with respect to the native
aortic annulus is critical to ensure a successful procedure,
whereas suboptimal deployment can result in incomplete
apposition of the valve and annulus or even worse in
incomplete sealing by the pericardial skirt of the stent frame
allowing a considerable diastolic backﬂow into the LV. For
malpositioned THVs with too shallow (“too aortic”) or too
deep (“too ventricular”) implantation of the prosthesis, valve-
in-valve implantation is a viable treatment strategy to reduce
signiﬁcant PAR and to prevent bailout cardiac surgery
(Fig. 6). The second valve can be deployed in a way that the
sealing pericardial skirts of both valves overlap and that the
second valve ensures sealing with the native valve annulus
(44). Thus, initial procedural failure can be converted into
procedural success in up to 90% of the attempts, and valve-
in-valve implantation results in comparable hemodynamicmoderate AR due to incomplete circumferential apposition of an Edwards SAPIEN
months after implantation of this accurately sized prosthesis with proper implantation
homechanism and identiﬁed the localized paravalvular leak (D). Passage of the
4F Judkins right coronary catheter, avoiding crossing through the stent struts of the
red by transvalvular insertion of an Amplatz Super Stiff wire via a 5F pigtail catheter
bolization. After deployment of an Amplatz Vascular Plug III under guidance with
graphy (E), the ARI increased to 30.8 (F) (51,52). Abbreviation as in Figure 5.
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19results with satisfactory short-term and midterm outcomes
(42,44,49). In addition, the valve-in-valve technique is
a viable treatment option for signiﬁcant transvalvular AR
due to severe prosthetic leaﬂet dysfunction and has impor-
tant implications for patients who develop late failure of
THVs, also in case of restenosis as a “re-do” procedure (50).
However, one major drawback of THV-in-THV implan-
tation with the Medtronic CoreValve is the restricted access
to the coronary ostia. In the near future, repositionability
and retrievability of THVs will be addressed by the next-
generation devices and help to reduce the occurrence of
malpositioning (4).
Snare Technique
The Snare technique represents an option worth considering
for a too deeply implanted Medtronic CoreValve (too
“ventricular” placement of the prosthesis) (Fig. 7). In this
case, correction of the device position may be achieved by
engaging one of the anchoring hooks and pulling with
a snare catheter (39). To increase the leverage effect, the
snaring maneuver can be performed via transbrachial access.
However, this corrective maneuver is not without hazards
(e.g., aortic dissection) and bears the potential risk of THV
embolization into the ascending aorta (6,40,45). If the
attempt to reposition a Medtronic CoreValve with the snare
technique fails, valve-in-valve implantation can be consid-
ered to prevent conversion to emergency open heart surgery.
Interventional Closure
Interventional closure of paravalvular leaks after TAVR has
been described for the Edwards SAPIEN prosthesis (51,52)
(Fig. 8). If the implantation depth of a THV is appropriate
and the THV is not undersized, balloon post-dilation can be
theﬁrst step to obtain a better expansion of the prosthesis stent
frame with improved sealing of the paravalvular space.
However, if signiﬁcant PAR remains because of heavy calci-
ﬁcations of the native aortic valve and a localizedAR jet can be
identiﬁed, transcatheter device closure with use of the
Amplatzer Vascular Plug III (AVP III, AGAMedical Corp.,
Plymouth, Minnesota) can be attempted analogous to para-
valvular leak closure in surgical heart valves (53). However,
potential risks associated with transcatheter device closure of
paravalvular leaks after TAVR include stroke, THV
dislodgment, and embolization of the closure device (52).
Future Developments
The reduction in the incidence and severity of PAR represents
an obvious target for technical improvements in the design
of upcoming “next-generation” THVs and of implantation
techniques (4): sealing mechanisms at the lower part of the
prosthesis skirt that help to conform to irregular surfaces of
the native anatomy or full repositionability and retrievability
to achieve an optimal procedural result with proper placement
of the prosthesis and a lesser extent of PAR.Conclusions
For the evaluation of PAR after TAVR, a multimodal
approach with the use of hemodynamic measurements and
imaging modalities is imperative to precisely quantify the
severity of AR immediately after valve implantation and to
identify patients who will beneﬁt from corrective measures,
such as post-dilation or valve-in-valve implantation. Every
measure has to be taken to prevent or reduce PAR to provide
a satisfying long-term clinical outcome.
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APPENDIX
For supplemental videos and their legends, please see the online version of
this article.
